Immunogen (IMGN), Merck (MRK) Enter FRα-Positive Ovarian Cancer Treatment R&D Collaboration
Tweet Send to a Friend
ImmunoGen, Inc. (Nasdaq: IMGN) and Merck (NYSE: MRK) announced that they have entered into a clinical research collaboration for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
